Hybrid µCT-FMT imaging and image analysis
June 4th, 2015
14.8K views
We describe a protocol for hybrid imaging, combining fluorescence-mediated tomography (FMT) with micro computed tomography (µCT). After fusion and reconstruction, we perform interactive organ segmentation to extract quantitative measurements of the fluorescence distribution.
Overview
This article presents a protocol for hybrid imaging that integrates fluorescence-mediated tomography (FMT) with micro computed tomography (µCT). The process includes interactive organ segmentation to quantitatively assess fluorescence distribution in anesthetized mice.
Key Study Components
Area of Science
- Neuroscience
- Imaging Techniques
- Fluorescence Tomography
Background
- Fluorescence-mediated tomography is a sensitive imaging method.
- It allows for the assessment of various biological processes in vivo.
- Micro CT provides detailed anatomical information.
- Combining these techniques enhances imaging capabilities.
Purpose of Study
- To develop a protocol for hybrid imaging using FMT and µCT.
- To enable quantitative measurements of fluorescence distribution.
- To improve organ segmentation for better data analysis.
Methods Used
- Preparation of anesthetized mice for imaging.
- Use of fluorescent and CT contrast agents.
- Implementation of interactive software for organ segmentation.
- Fusion of data from FMT and µCT for comprehensive analysis.
Main Results
- Successful integration of FMT and µCT imaging techniques.
- Quantitative assessment of fluorescence distribution achieved.
- Effective organ segmentation demonstrated through software.
- Enhanced understanding of biodistribution in biological studies.
Conclusions
- The hybrid imaging protocol provides valuable insights into biological processes.
- It allows for precise quantitative measurements in vivo.
- This method can be applied to various research areas in neuroscience.
Frequently Asked Questions
What is fluorescence-mediated tomography?
Fluorescence-mediated tomography is an imaging technique that quantitatively assesses fluorescence distribution in biological tissues.
How does hybrid imaging improve research?
Hybrid imaging combines the strengths of FMT and µCT, providing both functional and anatomical information for comprehensive analysis.
What are the main applications of this imaging technique?
This technique is used to study processes like angiogenesis, apoptosis, and inflammation in vivo.
What precautions should be taken during imaging?
Mice should be monitored for anesthesia effects, and care should be taken to avoid hypothermia and skin irritation.
How is data from FMT and µCT fused?
Data fusion is achieved using markers and specialized software that aligns and integrates the imaging data for analysis.
Executive Industry Relevance
Hybrid µCT-FMT imaging enables quantitative, longitudinal assessment of probe biodistribution and disease progression in preclinical models. Integrating anatomical and molecular imaging enhances spatial accuracy and supports robust translational workflows. This capability strengthens predictive confidence at key inflection points in discovery and preclinical research portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Supports quantitative evaluation of novel probe biodistribution in vivo.
- Enables functional mapping of disease-relevant biological processes such as angiogenesis and inflammation.
- Improves mechanistic de-risking by correlating molecular signals with anatomical context.
- Facilitates target validation through precise spatial and temporal fluorescence quantification.
Screening & Assay Development
- Prepares validated animal models for downstream imaging-based screening workflows.
- Delivers standardized, reproducible quantitative outputs for probe and reporter evaluation.
- Enables batch processing and high-throughput analysis of organ-specific fluorescence data.
- Supports assay development by providing robust anatomical segmentation and data integration.
Translational & Preclinical Research
- Aligns molecular imaging readouts with anatomical structures for translational biomarker development.
- Ensures continuity from early discovery through preclinical validation by enabling longitudinal studies.
- Reduces biological risk by providing quantitative, organ-level biodistribution curves.
- Facilitates risk-adjusted advancement decisions based on robust in vivo data.
Pipeline & Workflow Integration
This hybrid imaging protocol bridges early discovery, lead identification, and preclinical validation by enabling quantitative, organ-specific analysis of probe distribution and disease progression in vivo.
- Discovery Biology: Provides high-sensitivity, quantitative imaging for hypothesis testing and pathway mapping.
- Screening: Delivers reproducible, standardized outputs suitable for comparative analysis across conditions and time points.
- Analytics: Generates batch-processed, quantitative biodistribution data for statistical evaluation.
- Translational Research: Supports biomarker alignment and preclinical model validation through integrated anatomical and molecular imaging.
- Enterprise Reuse: Offers a scalable, reusable imaging and analysis workflow adaptable to diverse probe and disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in probe and target evaluation.
- Operational Value: Standardizes imaging, segmentation, and analysis for reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of discovery and preclinical assets.
Implementation Considerations
- Requires expertise in small animal imaging and quantitative image analysis.
- Demands access to µCT and FMT instrumentation and integrated analytical software.
- Necessitates cross-team standardization of imaging protocols and segmentation workflows.
- Adaptation may be needed for different animal strains or probe types.
- Manual segmentation can be labor-intensive for large cohorts or longitudinal studies.
Biopharma FAQs
Why does null hypothesis testing matter for quantitative fluorescence reconstruction?
Null hypothesis testing ensures that observed fluorescence distributions are statistically significant and not due to random variation, supporting robust target validation. This is critical for distinguishing true biological signals from background noise in quantitative imaging workflows.
How does independent variable isolation fit in organ segmentation analysis?
Isolating independent variables, such as specific organ regions, enables precise attribution of fluorescence signals to anatomical structures. This supports accurate assessment of probe biodistribution and disease progression in preclinical models.
What do quantitative dependent variable measurements enable in batch statistics?
Quantitative measurements of dependent variables, like organ-specific fluorescence intensity, enable batch statistical analysis across multiple scans and time points. This facilitates comparative evaluation and trend identification in longitudinal studies.
Why are replication requirements important for multimodal imaging workflows?
Replication ensures that multimodal imaging results are reproducible and reliable across different animals and experimental runs. This is essential for cross-functional collaboration and for building confidence in translational research findings.
Which statistical analysis capabilities are required before implementing batch biodistribution analysis?
Robust statistical analysis capabilities, including batch processing and quantitative comparison of organ-level data, are required to ensure valid interpretation of biodistribution curves. These capabilities support data-driven decision-making in preclinical R&D pipelines.
